BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26104880)

  • 1. Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.
    Xu H; Zhang H; Yang W; Yadav R; Morrison AC; Qian M; Devidas M; Liu Y; Perez-Andreu V; Zhao X; Gastier-Foster JM; Lupo PJ; Neale G; Raetz E; Larsen E; Bowman WP; Carroll WL; Winick N; Williams R; Hansen T; Holm JC; Mardis E; Fulton R; Pui CH; Zhang J; Mullighan CG; Evans WE; Hunger SP; Gupta R; Schmiegelow K; Loh ML; Relling MV; Yang JJ
    Nat Commun; 2015 Jun; 6():7553. PubMed ID: 26104880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of CDKN2A, CDKN2B and MTAP in childhood B-lineage acute lymphobastic leukemia.
    Beverloo HB
    Haematologica; 2006 Jul; 91(7):865B. PubMed ID: 16818264
    [No Abstract]   [Full Text] [Related]  

  • 3. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.
    Brown AL; de Smith AJ; Gant VU; Yang W; Scheurer ME; Walsh KM; Chernus JM; Kallsen NA; Peyton SA; Davies GE; Ehli EA; Winick N; Heerema NA; Carroll AJ; Borowitz MJ; Wood BL; Carroll WL; Raetz EA; Feingold E; Devidas M; Barcellos LF; Hansen HM; Morimoto L; Kang AY; Smirnov I; Healy J; Laverdière C; Sinnett D; Taub JW; Birch JM; Thompson P; Spector LG; Pombo-de-Oliveira MS; DeWan AT; Mullighan CG; Hunger SP; Pui CH; Loh ML; Zwick ME; Metayer C; Ma X; Mueller BA; Sherman SL; Wiemels JL; Relling MV; Yang JJ; Lupo PJ; Rabin KR
    Blood; 2019 Oct; 134(15):1227-1237. PubMed ID: 31350265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population.
    Gutierrez-Camino A; Martin-Guerrero I; Garcia de Andoin N; Sastre A; Carbone Bañeres A; Astigarraga I; Navajas A; Garcia-Orad A
    PLoS One; 2017; 12(5):e0177421. PubMed ID: 28481918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.
    Mirebeau D; Acquaviva C; Suciu S; Bertin R; Dastugue N; Robert A; Boutard P; Méchinaud F; Plouvier E; Otten J; Vilmer E; Cavé H;
    Haematologica; 2006 Jul; 91(7):881-5. PubMed ID: 16818274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia.
    Li C; Zhao X; He Y; Li Z; Qian J; Zhang L; Ye Q; Qiu F; Lian P; Qian M; Zhang H
    Pharmacogenet Genomics; 2022 Feb; 32(2):43-50. PubMed ID: 34369425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of IKZF1 and CDKN2A gene polymorphisms with childhood acute lymphoblastic leukemia: a high-resolution melting analysis.
    Sattarzadeh Bardsiri M; Zehtab S; Karami N; Farsinejad A; Ehsan M; Fatemi A
    BMC Med Genomics; 2022 Aug; 15(1):171. PubMed ID: 35932035
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lopes BA; Barbosa TC; Souza BKS; Poubel CP; Pombo-de-Oliveira MS; Emerenciano M;
    Cancer Prev Res (Phila); 2017 Dec; 10(12):738-744. PubMed ID: 28947432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
    Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
    Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A.
    Vijayakrishnan J; Henrion M; Moorman AV; Fiege B; Kumar R; da Silva Filho MI; Holroyd A; Koehler R; Thomsen H; Irving JA; Allan JM; Lightfoot T; Roman E; Kinsey SE; Sheridan E; Thompson PD; Hoffmann P; Nöthen MM; Mühleisen TW; Eisele L; Bartram CR; Schrappe M; Greaves M; Hemminki K; Harrison CJ; Stanulla M; Houlston RS
    Sci Rep; 2015 Oct; 5():15065. PubMed ID: 26463672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia.
    Zhou X; Liao F; Zhang J; Qin Y; Xu H; Ding Z; Zhang Y; Zhang F
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29654170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.
    Pastorczak A; Górniak P; Sherborne A; Hosking F; Trelińska J; Lejman M; Szczepański T; Borowiec M; Fendler W; Kowalczyk J; Houlston RS; Młynarski W
    Leuk Res; 2011 Nov; 35(11):1534-6. PubMed ID: 21889209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
    Kim M; Yim SH; Cho NS; Kang SH; Ko DH; Oh B; Kim TY; Min HJ; She CJ; Kang HJ; Shin HY; Ahn HS; Yoon SS; Kim BK; Shin HR; Han KS; Cho HI; Lee DS
    Cancer Genet Cytogenet; 2009 Nov; 195(1):59-65. PubMed ID: 19837270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
    Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
    Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contributions of IKZF1, DDC, CDKN2A, CEBPE, and LMO1 Gene Polymorphisms to Acute Lymphoblastic Leukemia in a Yemeni Population.
    Al-Absi B; Razif MFM; Noor SM; Saif-Ali R; Aqlan M; Salem SD; Ahmed RH; Muniandy S
    Genet Test Mol Biomarkers; 2017 Oct; 21(10):592-599. PubMed ID: 28768142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds.
    Gant VU; Junco JJ; Terrell M; Rashid R; Rabin KR
    PLoS One; 2021; 16(1):e0244863. PubMed ID: 33411777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Islet biology, the CDKN2A/B locus and type 2 diabetes risk.
    Kong Y; Sharma RB; Nwosu BU; Alonso LC
    Diabetologia; 2016 Aug; 59(8):1579-93. PubMed ID: 27155872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence.
    Gharbi H; Ben Hassine I; Soltani I; Safra I; Ouerhani S; Bel Haj Othmen H; Teber M; Farah A; Amouri H; Toumi NH; Abdennebi S; Abbes S; Menif S
    Pediatr Hematol Oncol; 2016 Apr; 33(3):157-67. PubMed ID: 27184773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
    Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
    Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.